Literature DB >> 10766163

Estrogen receptor protects p53 from deactivation by human double minute-2.

G Liu1, J A Schwartz, S C Brooks.   

Abstract

We and others have demonstrated that estrogen receptor alpha (ERalpha) and p53, two important regulatory proteins in breast cancer, bind to each other. In this report, using the glutathione S-transferase pull-down methodology, we show the ligand-independent interaction of ERalpha with the NH2-terminal region of p53, a region known to bind the p300 and human double minute-2 (hdm2) regulatory factors. Furthermore, we have demonstrated that ERalpha is capable of binding hdm2 directly. The interaction of ERalpha and p53 does not interfere with the binding between p53 and hdm2; rather, these proteins form a ternary complex. The effect of ERalpha on the p53-hdm2 regulatory loop has been examined. Our results indicate that ERalpha protects p53 from being deactivated by hdm2. It is evident from these investigations that the ligand-independent protection of p53 by ERalpha is a novel role for this protein in addition to its classic regulatory function as a ligand-inducible transcription factor. This study also describes a new mechanism of cellular regulation of p53 activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10766163

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  p53 and MDM2 are involved in the regulation of osteocalcin gene expression.

Authors:  Hankui Chen; Kevin Kolman; Natalie Lanciloti; Michael Nerney; Emily Hays; Chet Robson; Nalini Chandar
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

2.  A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model.

Authors:  Zhihe Liu; Guanghua Wan; Christopher Heaphy; Marco Bisoffi; Jeffrey K Griffith; Chien-An A Hu
Journal:  Mol Cell Biochem       Date:  2006-11-21       Impact factor: 3.396

Review 3.  Tumor suppressor p53 and estrogen receptors in nuclear-mitochondrial communication.

Authors:  Nadi T Wickramasekera; Gokul M Das
Journal:  Mitochondrion       Date:  2013-10-29       Impact factor: 4.160

4.  Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors.

Authors:  W Hu; P D McCrea; M Deavers; J J Kavanagh; A P Kudelka; C F Verschraegen
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1.

Authors:  Daniel Menendez; Alberto Inga; Joyce Snipe; Oliver Krysiak; Gilbert Schönfelder; Michael A Resnick
Journal:  Mol Cell Biol       Date:  2007-01-22       Impact factor: 4.272

Review 6.  Deconvoluting the obesity and breast cancer link: secretome, soil and seed interactions.

Authors:  Nikki A Ford; Kaylyn L Devlin; Laura M Lashinger; Stephen D Hursting
Journal:  J Mammary Gland Biol Neoplasia       Date:  2013-10-04       Impact factor: 2.673

Review 7.  Role of oestrogen receptors in bladder cancer development.

Authors:  Iawen Hsu; Spencer Vitkus; Jun Da; Shuyuan Yeh
Journal:  Nat Rev Urol       Date:  2013-04-16       Impact factor: 14.432

Review 8.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

9.  Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

10.  Estrogen receptor prevents p53-dependent apoptosis in breast cancer.

Authors:  Shannon T Bailey; Hyunjin Shin; Thomas Westerling; Xiaole Shirley Liu; Myles Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.